Wet Age-Related Macular Degeneration
Retina World Congress 2024 to highlight scientific, clinical advancements
One thousand physicians, health care providers and industry members will gather in Fort Lauderdale, Florida, in May for the Retina World Congress 2024 hosted in conjunction with Healio Live.
VIDEO: Delivery options for wet AMD gene therapy under investigation
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Lejla Vajzovic, MD, FASRS, discusses developments in gene therapy for wet age-related macular degeneration.
Q&A: Look for signs of AMD even in those without family history
Age-related macular degeneration can occur even in patients without a family history, so clinicians must be aware of early warning signs of the disease, according to Deborah Ferrington, PhD.
Leadership changes strengthen Ocular Therapeutix’s focus on retina care
Ocular Therapeutix announced changes to its leadership and board of directors to strengthen its focus on retina care.
Precursor lesions may help identify risk for atrophy in AMD
Lesion-level analysis on OCT can help identify risk for atrophy, according to a speaker at Angiogenesis, Exudation, and Degeneration 2024.
First patients screened in clinical trial of Axpaxli for wet AMD
Ocular Therapeutix announced that the first three participants have received an aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli, an axitinib intravitreal implant for wet age-related macular degeneration.
Enrollment complete in phase 3 trial of sozinibercept for wet AMD
Opthea Limited has completed enrollment of its COAST phase 3 clinical trial, a study of sozinibercept in combination with Eylea for wet age-related macular degeneration, the company announced in a press release.
VIDEO: Supplemental aflibercept did not influence outcomes of EYP-1901 in wet AMD
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Carl D. Regillo, MD, discusses the impact of supplemental aflibercept on eyes with wet age-related macular degeneration treated with EYP-1901.
FDA agrees to amend special protocol assessment for trial of Axpaxli in wet AMD
The FDA has agreed to a special protocol assessment agreement modification for Ocular Therapeutix’s phase 3 SOL clinical trial of Axpaxli, an axitinib intravitreal implant for treatment of wet age-related macular degeneration.
VIDEO: Faricimab dosing interval may extend up to 20 weeks in wet AMD, DME
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Michael A. Singer, MD, presents data on dosing intervals for faricimab as a treatment for wet age-related macular degeneration and diabetic macular edema.